Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Reimagining Mexico’s brain bank
Since Alzheimer’s disease researcher José Luna-Muñoz assumed leadership of the facility—Latin America’s oldest—in 2011, he has been acquiring additional tissue types and is working to expand donor recruitment to rural areas.
Reimagining Mexico’s brain bank
Since Alzheimer’s disease researcher José Luna-Muñoz assumed leadership of the facility—Latin America’s oldest—in 2011, he has been acquiring additional tissue types and is working to expand donor recruitment to rural areas.
Revealing how crabs make their escape
Houdini-like Neohelice granulata offers a rare opportunity to record intracellularly from awake, behaving animals.
Revealing how crabs make their escape
Houdini-like Neohelice granulata offers a rare opportunity to record intracellularly from awake, behaving animals.
Discovering how butterflies choose their mate
Heliconius butterflies offer a window into the neural circuits and genes involved in mate color preference.
Discovering how butterflies choose their mate
Heliconius butterflies offer a window into the neural circuits and genes involved in mate color preference.